Corbus says anti-inflammatory drug will enter late-stage trial this year

Norwood-based Corbus Pharmaceuticals said Wednesday that it plans to launch a Phase 3 trial of its sole drug in development in the fourth quarter of 2017, paving the way for a possible FDA filing in 2019. Corbus (Nasdaq: CRBP), the state’s top-performing public biotech last year, said that it planned to advance its anti-inflammatory drug anabasum into a single, year-long Phase 3 study for the treatment of scleroderma, a rare autoimmune disease. There is currently no approved treatment for the…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news